Capricor Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright
In a research report issued today, H.C. Wainwright analyst Reni Benjamin reiterated a Buy rating on Capricor Therapeutics (CAPR) with a price target of $8.00, which represents a potential upside of 110% from where the stock is currently trading.
Benjamin noted, “Yesterday, Capricor announced that the company’s lead therapeutic candidate, CAP-1002, will be evaluated in an additional indication, Duchenne Muscular Dystrophy (DMD). The new program is based on preclinical data scheduled for presentation at the American Heart Association’s (AHA) Scientific Sessions on November 17. We believe the new indication area, which expands Capricor’s pipeline beyond the ischemic heart failure market, represents an expansion of the company’s pipeline. With a regenerative medicine platform of diverse assets, Janssen Pharmaceuticals as a potential partner (potential opt-in upon positive 6-month results from the Phase 2 portion of the ALLSTAR trial), and a cash position of $11.9 MM, we believe Capricor represents an undervalued player with significant upside for the long-term investor.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Reni Benjamin has a total average return of -4.1% and a 30.2% success rate. Benjamin is ranked #3072 out of 3318 analysts.